Zoster Vaccine (Recombinant)  
SHINGRIX®  

Supplier: GlaxoSmithKline Inc.

**INDICATIONS:** This vaccine is not publicly funded.

**RECOMMENDED BY THE NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION BUT NOT PROVIDED FREE IN BC:**

- Should be offered to individuals 50 years of age and older for the prevention of shingles, including those who:
  - have been previously vaccinated with live zoster vaccine (ZOSTAVAX® II)
  - have had a previous episode of shingles

**DOSES AND SCHEDULE:**

**Individuals 50 years of age and older:** 2 doses given as 0.5 mL IM, 2 to 6 months apart.

**ADMINISTRATION:**

- Product needs to be reconstituted. Use the diluent provided with the vaccine.
- Administer the entire volume of the reconstituted product.

**BOOSTER DOSES:**

No booster doses are recommended at this time.

**SEROLOGICAL TESTING:**

Serological testing is not recommended before or after immunization.

**CONTRAINDICATIONS:**

1. History of anaphylactic reaction to a previous dose of SHINGRIX®, or to any component of SHINGRIX®.

**PRODUCT COMPONENTS:**

Potential allergens: polysorbate 80. 
Other components: *Quillaja saponaria* Molinara fraction 21, 3-O-desacyl-4'-monophosphoryl lipid A, dipotassium phosphate, sodium dihydrogen phosphate dihydrate, sucrose, cholesterol, dioleoyl phosphatidylcholine, disodium phosphate anhydrous, potassium dihydrogen phosphate.

---

**A** SHINGRIX® is indicated for the prevention of shingles in individuals with prior chickenpox infection. Given that nearly all Canadians eligible for this vaccine will have had prior varicella exposure, even if a diagnosis of varicella cannot be recalled, routine serological testing is not recommended. There is no known safety risk associated with vaccination of healthy individuals who are varicella-susceptible. However, in the rare circumstance that an individual is known to be serologically varicella susceptible, they should be immunized with 2 doses of varicella vaccine rather than zoster vaccine.

**B** There should be an interval of at least 1 year between receipt of live zoster vaccine and administration of SHINGRIX®.

**C** There should be an interval of at least 1 year between an episode of shingles and administration of SHINGRIX®.
Zoster Vaccine (Recombinant)  
SHINGRIX  
Supplier: GlaxoSmithKline Inc.

PRECAUTIONS:
• SHINGRIX® should be used with precaution in those who are pregnant or breastfeeding as there are no data on its use in these populations.

SPECIAL CONSIDERATIONS:
• SHINGRIX® may be considered for immunocompromised adults 50 years of age and older.

ADVERSE EVENTS:
Local: pain, redness, swelling.
Systemic: myalgia, fatigue, headache, shivering, fever, nausea, diarrhea, vomiting, stomach pain.